NUVL - Nuvalent, Inc.

107.13
-1.110   -1.036%

Share volume: 787,125
Last Updated: 04-21-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$108.24
-1.11
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
41%
Profitability 35%
Dept financing 20%
Liquidity 50%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
4.22%
1 Month
12.25%
3 Months
-0.73%
6 Months
11.38%
1 Year
54.74%
2 Year
67.84%
Key data
Stock price
$107.13
P/E Ratio 
0.00
DAY RANGE
$105.64 - $108.45
EPS 
-$5.54
52 WEEK RANGE
$63.56 - $113.02
52 WEEK CHANGE
$51.62
MARKET CAP 
7.314 B
YIELD 
N/A
SHARES OUTSTANDING 
78.617 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-07-2025
BETA 
1.31
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$523,786
AVERAGE 30 VOLUME 
$602,676
Company detail
CEO: James R. Porter
Region: US
Website: nuvalent.com
Employees: 40
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations.

Recent news